{"id":1487,"date":"2010-03-31T16:03:05","date_gmt":"2010-03-31T20:03:05","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/%e2%80%a2%c2%a0new-york-times-orbits-jupiter\/"},"modified":"2011-07-19T17:45:00","modified_gmt":"2011-07-19T21:45:00","slug":"new-york-times-orbits-jupiter","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2010\/03\/31\/new-york-times-orbits-jupiter\/","title":{"rendered":"New York Times Orbits JUPITER"},"content":{"rendered":"

A front page story in Wednesday’s\u00a0New York Times<\/em><\/a><\/em> questions the expanding use of statins, and particularly rosuvastatin, in “healthy people.” Following the recent approval of broad new indications for the drug based on results from the\u00a0JUPITER<\/a>\u00a0trial,\u00a0Times<\/em> reporter Duff Wilson notes that millions of people may now take the drug “largely as prevention” and that some experts “suggest the benefits may not outweigh any side effects.”<\/p>\n

The article quotes Stanford’s Mark Hlatky: \u201cIt\u2019s a good thing to be skeptical about whether there may be long-term harm from healthy people taking a drug like this.\u201d<\/p>\n

By contrast, JUPITER principal investigator and longtime advocate of CRP, Paul Ridker, told Wilson:\u00a0\u201cWe found a 55 percent reduction in heart attacks, 48 percent reduction in\u00a0stroke, 45 percent reduction in\u00a0angioplasty\u00a0bypass surgery.\u201d His view is supported by Steve Nissen:\u00a0\u201cIf somebody comes into my office and meets the criteria, am I going to deny them a drug that reduces their chance of a\u00a0heart attack\u00a0or stroke by 40 or 50 percent?\u201d<\/p>\n

But, the article notes, the absolute difference in heart attacks in JUPITER was only 0.2%.<\/p>\n

A quote from a cardiologist in Rockville Centre, NY, Steven Seiden, concludes the article:\u00a0\u201cIt just turns a lot of healthy people into patients and commits them to a lifetime of medication.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"

A front page story in Wednesday’s\u00a0New York Times questions the expanding use of statins, and particularly rosuvastatin, in “healthy people.” Following the recent approval of broad new indications for the drug based on results from the\u00a0JUPITER\u00a0trial,\u00a0Times reporter Duff Wilson notes that millions of people may now take the drug “largely as prevention” and that some […]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1487","post","type-post","status-publish","format-standard","hentry","category-general"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=1487"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/1487\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=1487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=1487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=1487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}